Should Sorrento Therapeutics Be Your Next Coronavirus Buy?

Sorrento Therapeutics (NASDAQ: SRNE) had good news for investors recently when it said its second candidate to fight coronavirus showed positive results in preclinical testing. That's after positive preclinical results in a first candidate last month. Does this mean Sorrento is the stock to add to your portfolio of players in the coronavirus treatment race?

Let's take a closer look at these two candidates -- and the rest of the Sorrento business.

Image source: Getty Images.

Source Fool.com